{"id":147738,"date":"2025-04-24T12:57:14","date_gmt":"2025-04-24T07:27:14","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=147738"},"modified":"2025-04-24T12:57:18","modified_gmt":"2025-04-24T07:27:18","slug":"pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/","title":{"rendered":"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2199600282\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3716997781\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Price Movement<\/strong><\/h2><p>With a market cap of Rs. 26,706.3 crores, at 11:51 a.m., the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/SYNGENE\" target=\"_blank\" rel=\"noreferrer noopener\">Syngene International Limited<\/a><\/strong> were trading in the red at Rs. 663.9, down by nearly 11.5 percent, compared to its previous closing price of Rs. 750.05.<\/p><p>So far in 2025, the stock has delivered negative returns of around 24 percent, and has fallen by about 8 percent in the last one month.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What\u2019s the News<\/strong><\/h2><p>The fluctuations in the share prices were observed after Syngene International Limited announced the financial results for Q4 FY25, through the latest filings with the stock exchanges on Wednesday, post-market hours.<\/p><div class=\"trade-content_5\" id=\"trade-3005288934\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>For Q4 FY25, Syngene International reported a consolidated revenue from operations of Rs. 1,018 crores, reflecting a growth of around 8 percent QoQ from Rs. 943.7 crores in Q3 FY25, and a year-on-year rise of around 11 percent from Rs. 917 crores in Q4 FY24. Notably, this is the first time the company\u2019s quarterly revenue from operations has crossed the Rs. 1,000 crore mark.<\/p><p>Net profit surged significantly to Rs. 183.3 crore in Q4 FY25, a significant 40 percent increase over the Rs. 131 crore reported in the previous quarter, but a 3 percent decline compared to Rs. 188.6 crore in Q4 FY24.<\/p><p>During the same period, EBITDA also improved to Rs. 344 crore, growing by 21 percent QoQ and 8.5 percent YoY, reflecting good underlying fundamentals. However, EBITDA margins stood at 34 percent in Q4 FY25, up from 30 percent in Q3 FY25, but down from 35 percent in Q4 FY24.<\/p><p>The company\u2019s Board has recommended a final dividend of Re. 1.25 per Equity Share for FY25. The record date is fixed as Friday, 27th June 2025, for the payment of the dividend.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Management Comments<\/strong><\/h2><p>Peter Bains, Managing Director and CEO of the company, stated that the highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the United States. This move has strengthened Syngene\u2019s position in the rapidly expanding biologics CDMO sector and provided a strategic entry point into the US market.&nbsp;<\/p><p>He noted that the company\u2019s biologics CDMO business experienced strong growth, driven by commercial manufacturing and the addition of new development projects. Furthermore, the research division saw continued momentum, supported by a high conversion rate of pilot projects into full-scale programs within discovery services.<\/p><div class=\"trade-content-10\" id=\"trade-2784207008\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Syngene is well-positioned to expand its market share, backed by a 30-year track record of delivering innovative science, high-quality solutions, and value to its growing global customer base.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>About the Company<\/strong><\/h2><p>Syngene International Limited is engaged in the business of providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.<\/p><p>Syngene\u2019s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&amp;D, cGMP manufacturing, formulation and analytical development, along with clinical development services.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Shivani Singh<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-2184500246\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY. Price Movement With a market cap of Rs. 26,706.3 crores, at [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[6616,948,936,3157,25303,10296,10295],"class_list":["post-147738","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-pharma-stock","tag-stock-market","tag-stock-market-news","tag-stock-to-watch","tag-syngene-international","tag-syngene-international-latest-news","tag-syngene-international-share-price"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock crashes 12% despite reporting 40% YoY increase in net profits - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits\" \/>\n<meta property=\"og:description\" content=\"During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-24T07:27:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-24T07:27:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/\",\"name\":\"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2025-04-24T07:27:14+00:00\",\"dateModified\":\"2025-04-24T07:27:18+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits - Trade Brains Features","description":"During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits","og_description":"During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-04-24T07:27:14+00:00","article_modified_time":"2025-04-24T07:27:18+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/","name":"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2025-04-24T07:27:14+00:00","dateModified":"2025-04-24T07:27:18+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"During Thursday\u2019s trading session, the shares of an integrated research, development, and manufacturing services company slumped nearly 12 percent on BSE, despite the company reporting Q4 FY25 financial results with a revenue from operations increase of 8 percent QoQ and nearly 11 percent YoY.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-crashes-12-despite-reporting-40-yoy-increase-in-net-profits\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock crashes 12% despite reporting 40% YoY increase in net profits"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=147738"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147738\/revisions"}],"predecessor-version":[{"id":147739,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147738\/revisions\/147739"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=147738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=147738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=147738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}